BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 26847053)

  • 1. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
    Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
    Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
    Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
    J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
    Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB
    J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
    Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
    Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
    Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
    Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
    Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
    J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
    Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
    Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
    Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
    Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
    PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
    Casadevall D; Gimeno J; Clavé S; Taus Á; Pijuan L; Arumí M; Lorenzo M; Menéndez S; Cañadas I; Albanell J; Serrano S; Espinet B; Salido M; Arriola E
    Oncotarget; 2015 Jun; 6(18):16215-26. PubMed ID: 26041880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
    Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
    Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
    Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
    Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
    Bubendorf L; Dafni U; Schöbel M; Finn SP; Tischler V; Sejda A; Marchetti A; Thunnissen E; Verbeken EK; Warth A; Sansano I; Cheney R; Speel EJM; Nonaka D; Monkhorst K; Hager H; Martorell M; Savic S; Kerr KM; Tan Q; Tsourti Z; Geiger TR; Kammler R; Schulze K; Das-Gupta A; Shames D; Peters S; Stahel RA;
    Lung Cancer; 2017 Sep; 111():143-149. PubMed ID: 28838386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological features and prognostic implications of EGFR/c-Met gene copy number and protein expression in non-small cell lung cancer].
    Ai T; Wang N; Li WW; Song LP
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):825-9. PubMed ID: 21223687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.